Global Partners GLP 深 滬
已收盤 11-06 16:00:00 美东时间
45.01
+3.340
+8.02%
華盛通- 最 高45.01
- 今 開43.98
- 成交量 16.02万股
- 最 低 41.21
- 昨 收 41.67
- 總市值 15.30亿
- 52周最高 54.29
- 市盈率 靜 21.36
- 換手率 0.47%
- 52周最低 37.275
- 委 比 -40.91%
- 總股本 3399.56万
- 歷史最高 55.445
- 量 比 1.92
- 振 幅 9.12%
- 歷史最低 -15.375
- 每 手 1
- 風險率 3.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Global Partners Q3 2026 Earnings Call Transcript
Global Partners (NYSE:GLP) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View...
11-06 23:14
Global Partners Q3 EPS $1.26 Misses $1.61 Estimate, Sales $6.684B Miss $7.412B Estimate
Global Partners (NYSE:GLP) reported quarterly earnings of $1.26 per share which missed the analyst consensus estimate of $1.61 by 21.74 percent. This is a 90.91 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $6.684 billion wh...
11-06 21:03
BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
BioVie Inc. (NASDAQ: BIVI) has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 2,962,500 shares of common stock at $1.60 per share in a registered direct offering, with concurrent issuance of warrants to purchase up to the same number of shares at $1.70 per share. The offering is expected to raise approximately $4.74 million, net of expenses, to be used for working capital and general corporat...
11-04 13:00
INmune Bio, Inc. Announces Pricing of $4.50 Million Registered Direct Offering and Concurrent Private Placement
INmune Bio Inc. has completed a registered direct offering of 3,000,000 common shares and warrants to purchase an additional 3,000,000 shares, raising approximately $4.5 million. The warrants have an exercise price of $1.65, are exercisable six months after issuance, and expire in 5.5 years. Proceeds will be used for working capital and general corporate purposes. The offering is underwritten by A.G.P./Alliance Global Partners and registered with...
10-28 12:00
NeOnc Breaks Through Key Levels, as Brain-Cancer Stock’s Catalysts Continue
NeOnc Technologies Holdings (NASDAQ:NTHI) has seen its stock price break above $3, supported by strong trading volume and improving technical indicators, signaling a potential reversal. The company has also reported increased short interest, which could amplify volatility. NeOnc recently announced a Memorandum of Understanding with Abu Dhabi's Department of Health, advancing its brain tumor therapies, and shared positive clinical observations fro...
10-23 17:01
Oxford Lane Capital Corp. Prices Preferred Stock Offering
Oxford Lane Capital Corp. has priced an additional 1,440,000 shares of its 8.25% Series 2031 Term Preferred Shares at $24.85 per share, raising $35,784,000 in gross proceeds. The underwriters have a 30-day option to purchase up to 216,000 additional shares. The Preferred Stock will be treated as a single series with the Existing Preferred Stock, with the same terms and CUSIP. Upon issuance, there will be 4,200,000 shares outstanding. The net proc...
10-22 12:00
This Exelon Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Piper Sandler analyst Anna Andreeva upgraded VF Corp (NYSE:VFC) from Neutral to Overweight and ra...
10-13 21:26
Tilray Brands (TLRY) Q1 FY2027 Earnings Call: Revenue Up 23%, Guidance Reaffirmed
Tilray Brands Q1 FY2027 revenue rose 23% to $257.1 million as BrewDog and international operations grew. FY2027 EBITDA guidance was reaffirmed.
10-08 20:00
NeOnc’s FDA Catalyst Run Could Give NTHI a Serious Jolt
NeOnc Technologies Holdings (NASDAQ: NTHI) is gaining attention as Roth Capital initiates a Buy rating, adding to existing Wall Street optimism. Key upcoming events include an expected October FDA discussion for NEO100 and NeOnc's November 17 meeting for NEO212. NEO100's Phase 2a study met its primary endpoint, showing a 48.9% six-month progression-free survival rate, compared to a historical benchmark of 20%. NEO100 has received FDA Orphan Drug,...
10-06 13:02
